{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:16:42Z","timestamp":1789139802582,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Takeda"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Gaucher disease (GD) is a rare autosomal recessive condition associated with clinical features such as splenomegaly, hepatomegaly, anemia, thrombocytopenia, and bone abnormalities. Three clinical forms of GD have been defined based on the absence (type 1, GD1) or presence (types 2 and 3) of neurological signs. Early diagnosis can reduce the likelihood of severe, often irreversible complications. The aim of this study was to validate the ability of factors from the Gaucher Earlier Diagnosis Consensus (GED-C) scoring system to discriminate between patients with GD1 and controls using real-world data from electronic patient medical records from Maccabi Healthcare Services, Israel\u2019s second-largest state-mandated healthcare provider.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We applied the GED-C scoring system to 265 confirmed cases of GD and 3445 non-GD controls matched for year of birth, sex, and socioeconomic status identified from 1998 to 2022. The analyses were based on two databases: (1) all available data and (2) all data except free-text notes. Features from the GED-C scoring system applicable to GD1 were extracted for each individual. Patients and controls were compared for the proportion of the specific features and overall GED-C scores. Decision tree and random forest models were trained to identify the main features distinguishing GD from non-GD controls.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The GED-C scoring distinguished individuals with GD from controls using both databases. Decision tree models for the databases showed good accuracy (0.96 [95% CI 0.95\u20130.97] for Database 1; 0.95 [95% CI 0.94\u20130.96] for Database 2), high specificity (0.99 [95% CI 0.99\u20131]) for Database 1; 1.0 [95% CI 0.99\u20131] for Database 2), but relatively low sensitivity (0.53 [95% CI 0.46\u20130.59] for Database 1; 0.32 [95% CI 0.25\u20130.38]) for Database 2). The clinical features of splenomegaly, thrombocytopenia (&lt;\u200950\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L), and hyperferritinemia (300\u20131000\u00a0ng\/mL) were found to be the three most accurate classifiers of GD in both databases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In this analysis of real-world patient data, certain individual features of the GED-C score discriminate more successfully between patients with GD and controls than the overall score. An enhanced diagnostic model may lead to earlier, reliable diagnoses of Gaucher disease, aiming to minimize the severe complications associated with this disease.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-024-03042-y","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T16:03:20Z","timestamp":1708099400000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Assessing the diagnostic utility of the Gaucher Earlier Diagnosis Consensus (GED-C) scoring system using real-world data"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9151-0337","authenticated-orcid":false,"given":"Shoshana","family":"Revel-Vilk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varda","family":"Shalev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidan","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ora","family":"Paltiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orly","family":"Manor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avraham","family":"Tenenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liat","family":"Azani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Chodick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,16]]},"reference":[{"key":"3042_CR1","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3390\/ijms18020441","volume":"18","author":"J Stirnemann","year":"2017","unstructured":"Stirnemann J, et al. A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci. 2017;18:441.","journal-title":"Int J Mol Sci"},{"key":"3042_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ymgmr.2017.10.011","volume":"14","author":"IVD Schwartz","year":"2018","unstructured":"Schwartz IVD, et al. Characteristics of 26 patients with type 3 Gaucher disease: a descriptive analysis from the Gaucher outcome survey. Mol Genet Metab Rep. 2018;14:73\u20139.","journal-title":"Mol Genet Metab Rep"},{"key":"3042_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ymgme.2016.12.001","volume":"120","author":"A El-Beshlawy","year":"2017","unstructured":"El-Beshlawy A, et al. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the international collaborative Gaucher group Gaucher registry. Mol Genet Metab. 2017;120:47\u201356.","journal-title":"Mol Genet Metab"},{"key":"3042_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3390\/jcm12010085","volume":"12","author":"G Castillon","year":"2022","unstructured":"Castillon G, Chang SC, Moride Y. Global incidence and prevalence of Gaucher disease: a targeted literature review. J Clin Med. 2022;12:85.","journal-title":"J Clin Med"},{"key":"3042_CR5","first-page":"1189","volume-title":"Williams Hematology","author":"S Revel-Vilk","year":"2021","unstructured":"Revel-Vilk S, Szer J, Zimran A. Gaucher disease and related lysosomal storage diseases. In: Williams Hematology. New York: McGraw-Hill Education; 2021. p. 1189\u2013202."},{"key":"3042_CR6","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/ajh.23381","volume":"88","author":"DE Gonzalez","year":"2013","unstructured":"Gonzalez DE, et al. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: results from a randomized, double-blind, multinational, Phase 3 study. Am J Hematol. 2013;88:166\u201371.","journal-title":"Am J Hematol"},{"key":"3042_CR7","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/ajh.24012","volume":"90","author":"DA Hughes","year":"2015","unstructured":"Hughes DA, et al. Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: long-term data from phase III clinical trials. Am J Hematol. 2015;90:584\u201391.","journal-title":"Am J Hematol"},{"key":"3042_CR8","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/j.1365-2141.2009.07872.x","volume":"147","author":"PK Mistry","year":"2009","unstructured":"Mistry PK, et al. Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis. Br J Haematol. 2009;147:561\u201370.","journal-title":"Br J Haematol"},{"key":"3042_CR9","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ymgme.2017.08.002","volume":"122","author":"A Mehta","year":"2017","unstructured":"Mehta A, et al. Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians. Mol Genet Metab. 2017;122:122\u20139.","journal-title":"Mol Genet Metab"},{"key":"3042_CR10","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ajh.21888","volume":"86","author":"PK Mistry","year":"2011","unstructured":"Mistry PK, et al. A reappraisal of Gaucher disease-diagnosis and disease management algorithms. Am J Hematol. 2011;86:110\u20135.","journal-title":"Am J Hematol"},{"key":"3042_CR11","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/ajh.20908","volume":"82","author":"PK Mistry","year":"2007","unstructured":"Mistry PK, Sadan S, Yang R, Yee J, Yang M. Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention. Am J Hematol. 2007;82:697\u2013701.","journal-title":"Am J Hematol"},{"key":"3042_CR12","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/imj.14156","volume":"49","author":"A Mehta","year":"2019","unstructured":"Mehta A, et al. Presenting signs and patient co-variables in Gaucher disease: outcome of the Gaucher earlier diagnosis consensus (GED-C) Delphi initiative. Intern Med J. 2019;49:578\u201391.","journal-title":"Intern Med J"},{"key":"3042_CR13","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1111\/imj.14942","volume":"50","author":"A Mehta","year":"2020","unstructured":"Mehta A, et al. Scoring system to facilitate diagnosis of Gaucher disease. Intern Med J. 2020;50:1538\u201346.","journal-title":"Intern Med J"},{"key":"3042_CR14","doi-asserted-by":"publisher","first-page":"100725","DOI":"10.1016\/j.ymgmr.2021.100725","volume":"27","author":"MJ Savolainen","year":"2021","unstructured":"Savolainen MJ, et al. The Gaucher earlier diagnosis consensus point-scoring system (GED-C PSS): evaluation of a prototype in Finnish Gaucher disease patients and feasibility of screening retrospective electronic health record data for the recognition of potential undiagnosed patients in Finland. Mol Genet Metab Rep. 2021;27:100725.","journal-title":"Mol Genet Metab Rep"},{"key":"3042_CR15","first-page":"506","volume":"2","author":"S Revel-Vilk","year":"2022","unstructured":"Revel-Vilk S, et al. Using the Gaucher earlier diagnosis consensus (GED-C) delphi score in a real-world dataset. Int J Transl Med. 2022;2:506\u201314.","journal-title":"Int J Transl Med"},{"key":"3042_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4097\/kja.21209","volume":"75","author":"FS Nahm","year":"2022","unstructured":"Nahm FS. Receiver operating characteristic curve: overview and practical use for clinicians. Korean J Anesthesiol. 2022;75:25\u201336.","journal-title":"Korean J Anesthesiol"},{"key":"3042_CR17","doi-asserted-by":"publisher","first-page":"e0186674","DOI":"10.1371\/journal.pone.0186674","volume":"12","author":"RE Curovic","year":"2017","unstructured":"Curovic RE, et al. Splenomegaly - diagnostic validity, work-up, and underlying causes. PLoS ONE. 2017;12:e0186674.","journal-title":"PLoS ONE"},{"key":"3042_CR18","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s13075-019-2092-7","volume":"21","author":"L Jamian","year":"2019","unstructured":"Jamian L, Wheless L, Crofford LJ, Barnado A. Rule-based and machine learning algorithms identify patients with systemic sclerosis accurately in the electronic health record. Arthritis Res Ther. 2019;21:305.","journal-title":"Arthritis Res Ther"},{"key":"3042_CR19","doi-asserted-by":"publisher","first-page":"E617","DOI":"10.9778\/cmajo.20170036","volume":"5","author":"KL Tang","year":"2017","unstructured":"Tang KL, Lucyk K, Quan H. Coder perspectives on physician-related barriers to producing high-quality administrative data: a qualitative study. CMAJ Open. 2017;5:E617-622.","journal-title":"CMAJ Open"},{"key":"3042_CR20","doi-asserted-by":"publisher","first-page":"100911","DOI":"10.1016\/j.ymgmr.2022.100911","volume":"33","author":"M Pehrsson","year":"2022","unstructured":"Pehrsson M, et al. Screening for potential undiagnosed Gaucher disease patients: utilisation of the Gaucher earlier diagnosis consensus point-scoring system (GED-C PSS) in conjunction with electronic health record data, tissue specimens, and small nucleotide polymorphism (SNP) genotype data available in Finnish biobanks. Mol Genet Metab Rep. 2022;33:100911.","journal-title":"Mol Genet Metab Rep"},{"key":"3042_CR21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13326-018-0179-8","volume":"9","author":"A N\u00e9v\u00e9ol","year":"2018","unstructured":"N\u00e9v\u00e9ol A, Dalianis H, Velupillai S, Savova G, Zweigenbaum P. Clinical Natural Language Processing in languages other than English: opportunities and challenges. J Biomed Semant. 2018;9:12.","journal-title":"J Biomed Semant"},{"key":"3042_CR22","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/jbmr.3734","volume":"34","author":"D Hughes","year":"2019","unstructured":"Hughes D, et al. Gaucher disease in bone: from pathophysiology to practice. J Bone Miner Res. 2019;34:996\u20131013.","journal-title":"J Bone Miner Res"},{"key":"3042_CR23","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ymgme.2008.12.001","volume":"96","author":"P Mikosch","year":"2009","unstructured":"Mikosch P, et al. Patients with Gaucher disease living in England show a high prevalence of vitamin D insufficiency with correlation to osteodensitometry. Mol Genet Metab. 2009;96:113\u201320.","journal-title":"Mol Genet Metab"},{"key":"3042_CR24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1203\/00006450-200207000-00020","volume":"52","author":"S Rite","year":"2002","unstructured":"Rite S, et al. Insulin-like growth factors in childhood-onset Gaucher disease. Pediatr Res. 2002;52:109\u201312.","journal-title":"Pediatr Res"},{"key":"3042_CR25","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1615\/CritRevOncog.2013006145","volume":"18","author":"PK Mistry","year":"2013","unstructured":"Mistry PK, Taddei T, vom Dahl S, Rosenbloom BE. Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism. Crit Rev Oncog. 2013;18:235\u201346.","journal-title":"Crit Rev Oncog"},{"key":"3042_CR26","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1136\/ard-2022-222626","volume":"82","author":"R Knevel","year":"2023","unstructured":"Knevel R, Liao KP. From real-world electronic health record data to real-world results using artificial intelligence. Ann Rheum Dis. 2023;82:306\u201311.","journal-title":"Ann Rheum Dis"},{"key":"3042_CR27","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12911-023-02190-8","volume":"23","author":"D Riskin","year":"2023","unstructured":"Riskin D, et al. Using artificial intelligence to identify patients with migraine and associated symptoms and conditions within electronic health records. BMC Med Inform Decis Mak. 2023;23:121.","journal-title":"BMC Med Inform Decis Mak"},{"key":"3042_CR28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13023-019-1040-6","volume":"14","author":"S Ronicke","year":"2019","unstructured":"Ronicke S, et al. Can a decision support system accelerate rare disease diagnosis? Evaluating the potential impact of Ada DX in a retrospective study. Orphanet J Rare Dis. 2019;14:69.","journal-title":"Orphanet J Rare Dis"},{"key":"3042_CR29","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41591-018-0279-0","volume":"25","author":"Y Gurovich","year":"2019","unstructured":"Gurovich Y, et al. Identifying facial phenotypes of genetic disorders using deep learning. Nat Med. 2019;25:60\u20134.","journal-title":"Nat Med"},{"key":"3042_CR30","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s13023-023-02868-2","volume":"18","author":"A Wilson","year":"2023","unstructured":"Wilson A, et al. Development of a rare disease algorithm to identify persons at risk of Gaucher disease using electronic health records in the United States. Orphanet J Rare Dis. 2023;18:280.","journal-title":"Orphanet J Rare Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03042-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-024-03042-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03042-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T16:03:44Z","timestamp":1708099424000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-024-03042-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,16]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3042"],"URL":"https:\/\/doi.org\/10.1186\/s13023-024-03042-y","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,16]]},"assertion":[{"value":"28 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study design was approved by MHS Institutional Review Board (0013\u201321-ASMC). Patient consent was waived owing to the use of de-identified, anonymized data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patient consent was waived owing to the use of  de-identified, anonymized data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SRV has received research grants, speaker fees, and travel support from Pfizer, Sanofi Genzyme, and Takeda; VS is the chief marketing officer of Alike and has received speaker fees from Novartis and Roche; AG is a former employee and a stockholder of Takeda; LA and GC are employees of MaccabiTech; and OP, OM, and AT declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}